Advertisement
ABBV or REGN or ZTS
Which Stock Would AI Choose? AbbVie (ABBV) vs. Regeneron Pharmaceuticals (REGN) vs. Zoetis (ZTS) Stock Comparison
Key Takeaways
- ABBV has shown resilience in recent market activity, closing around $213 amid broader healthcare sector pressures, supported by analyst buy ratings and a price target implying 16% upside.
- REGN delivered strong one-year returns of about 18%, bolstered by robust demand for Dupixent and positive earnings beats, though facing short-term volatility.
- ZTS experienced downward pressure with shares near 52-week lows around $116, linked to companion animal market challenges despite solid Q4 2025 revenue growth.
- All three stocks operate in animal/human health-related pharma, but REGN exhibits superior relative momentum over the past year compared to ABBV's flat performance and ZTS's declines.
- Analyst consensus leans "Buy" across the board, with ABBV and REGN showing stronger growth prospects than ZTS in recent outlooks.
- Recent price action reflects sector headwinds, with ABBV holding steadier than peers amid earnings anticipation.
Introduction
This comparison examines ABBV (AbbVie), REGN (Regeneron Pharmaceuticals), and ZTS (Zoetis), three leaders in the healthcare sector spanning human pharmaceuticals, biotechnology, and animal health. Investors and traders focused on defensive growth in biotech and pharma will find value here, as these stocks highlight contrasts in momentum, pipeline strength, and market positioning amid recent volatility. With broader healthcare sentiment influenced by earnings cycles and regulatory developments, understanding their relative performance aids portfolio allocation in a dynamic environment.
ABBV Overview and Recent Performance
AbbVie Inc. (ABBV), a biopharmaceutical giant, specializes in immunology, oncology, neuroscience, and therapeutics like Humira successors Skyrizi and Rinvoq. In recent weeks, ABBV shares have demonstrated resilience, trading around $213 after dipping from mid-$230s peaks earlier in March. This stability stems from analyst optimism, with a consensus "Buy" rating and average price target of $248, suggesting over 16% upside. Sentiment has been buoyed by expectations for Q1 2026 earnings on April 24, following prior beats, though broader market fluctuations and patent dynamics weigh on volatility. Volume spikes during pullbacks indicate accumulation, positioning ABBV as a relative outperformer in recent market activity.
REGN Overview and Recent Performance
Regeneron Pharmaceuticals Inc. (REGN) focuses on biotechnology, developing treatments for eye diseases (Eylea), allergies/inflammation (Dupixent), and oncology via its VelociSuite platform. Recent market activity saw REGN fluctuate around $740-$750, down from $790 highs but up 18% over the past year versus S&P 500's 14%. Strong Q4 2025 results, with $11.44 EPS beating estimates by 18%, and Dupixent's global expansion, including Japan approvals, have driven positive momentum. Analyst upgrades and a "Buy" consensus with $820 targets reflect pipeline confidence, though Eylea competition introduces risks. Elevated volumes during swings highlight trader interest.
ZTS Overview and Recent Performance
Zoetis Inc. (ZTS), the world's leading animal health company, offers vaccines, medicines, and diagnostics for companion animals and livestock. Shares have faced pressure in recent weeks, hitting 52-week lows near $113-$116 amid a 28% annual decline, contrasting YTD gains of 7%. Q4 2025 revenue rose 3% to $2.4 billion with EPS of $1.48 beating forecasts, but U.S. companion animal softness and competition tempered sentiment. Guidance for 3-5% organic growth in 2026 provides a floor, yet volume surges on down days signal caution. ZTS's stability in livestock offsets pet market headwinds.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform's top-performing AI trading bots, curated from hundreds available that trade thousands of tickers across diverse strategies like momentum, pattern recognition, and sector rotation. Only those excelling in current conditions—such as volatile healthcare—earn a spot, with recent standouts posting 30-day annualized returns up to 171%, win rates of 70-100%, and profit factors exceeding 2.5. For instance, bots targeting semis and energy have delivered 168-227% annualized gains with low drawdowns. These vary by timeframe (e.g., 15-60 minutes), style (swing to scalping), and focus, enabling users to match market phases. Explore Trending AI Robots to deploy high-probability signals tailored to stocks like ABBV, REGN, and ZTS.
Head-to-Head Comparison
ABBV, REGN, and ZTS share healthcare exposure but diverge in models: ABBV's diversified pharma pipeline contrasts REGN's biotech focus on breakthroughs like Dupixent versus ZTS's recession-resistant animal health. Growth drivers favor REGN (pipeline catalysts) over ZTS's steady 6% organic revenue and ABBV's immunology reliance. Recent momentum tilts to REGN (18% 1Y return) ahead of ABBV (flat) and lagging ZTS. Risks include ABBV/ REGN patent cliffs versus ZTS pet spending sensitivity. Valuation sensitivity shows ABBV at higher P/E (~88x) due to earnings growth, REGN balanced (~17x), ZTS pressured. Sentiment is strongest for REGN post-earnings.
Tickeron AI Verdict
Tickeron’s AI currently favors REGN due to consistent trend strength, superior relative one-year performance, and pipeline catalysts like Dupixent expansion amid stable biotech sentiment. While ABBV offers defensive positioning and ZTS long-term stability, REGN's momentum and analyst alignment suggest higher probability of near-term outperformance in the current environment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ABBV’s FA Score shows that 2 FA rating(s) are green whileREGN’s FA Score has 1 green FA rating(s), and ZTS’s FA Score reflects 2 green FA rating(s).
- ABBV’s FA Score: 2 green, 3 red.
- REGN’s FA Score: 1 green, 4 red.
- ZTS’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABBV’s TA Score shows that 5 TA indicator(s) are bullish while REGN’s TA Score has 2 bullish TA indicator(s), and ZTS’s TA Score reflects 4 bullish TA indicator(s).
- ABBV’s TA Score: 5 bullish, 5 bearish.
- REGN’s TA Score: 2 bullish, 7 bearish.
- ZTS’s TA Score: 4 bullish, 6 bearish.
Price Growth
ABBV (@Pharmaceuticals: Major) experienced а -0.43% price change this week, while REGN (@Biotechnology) price change was -1.70% , and ZTS (@Pharmaceuticals: Generic) price fluctuated -0.07% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.86%. For the same industry, the average monthly price growth was -2.62%, and the average quarterly price growth was +6.54%.
The average weekly price growth across all stocks in the @Biotechnology industry was +1.04%. For the same industry, the average monthly price growth was -3.95%, and the average quarterly price growth was +5.21%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +3.18%. For the same industry, the average monthly price growth was +3.88%, and the average quarterly price growth was -0.58%.
Reported Earning Dates
ABBV is expected to report earnings on Apr 29, 2026.
REGN is expected to report earnings on Apr 29, 2026.
ZTS is expected to report earnings on May 07, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-0.86% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
@Biotechnology (+1.04% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Pharmaceuticals: Generic (+3.18% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
| ABBV | REGN | ZTS | |
| Capitalization | 368B | 79.2B | 49.6B |
| EBITDA | 17.6B | 5.82B | 4.07B |
| Gain YTD | -8.262 | -2.863 | -5.926 |
| P/E Ratio | 87.74 | 18.05 | 19.58 |
| Revenue | 61.2B | 14.3B | 9.47B |
| Total Cash | 5.26B | 8.61B | 2.31B |
| Total Debt | 67.5B | 2.71B | 9.24B |
ABBV | REGN | ZTS | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 62 | 12 | 7 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 37 Fair valued | 3 Undervalued | 29 Undervalued | |
PROFIT vs RISK RATING 1..100 | 14 | 75 | 100 | |
SMR RATING 1..100 | 1 | 53 | 16 | |
PRICE GROWTH RATING 1..100 | 58 | 47 | 61 | |
P/E GROWTH RATING 1..100 | 40 | 36 | 86 | |
SEASONALITY SCORE 1..100 | 2 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
REGN's Valuation (3) in the Biotechnology industry is in the same range as ZTS (29) in the Pharmaceuticals Generic industry, and is somewhat better than the same rating for ABBV (37) in the Pharmaceuticals Major industry. This means that REGN's stock grew similarly to ZTS’s and somewhat faster than ABBV’s over the last 12 months.
ABBV's Profit vs Risk Rating (14) in the Pharmaceuticals Major industry is somewhat better than the same rating for REGN (75) in the Biotechnology industry, and is significantly better than the same rating for ZTS (100) in the Pharmaceuticals Generic industry. This means that ABBV's stock grew somewhat faster than REGN’s and significantly faster than ZTS’s over the last 12 months.
ABBV's SMR Rating (1) in the Pharmaceuticals Major industry is in the same range as ZTS (16) in the Pharmaceuticals Generic industry, and is somewhat better than the same rating for REGN (53) in the Biotechnology industry. This means that ABBV's stock grew similarly to ZTS’s and somewhat faster than REGN’s over the last 12 months.
REGN's Price Growth Rating (47) in the Biotechnology industry is in the same range as ABBV (58) in the Pharmaceuticals Major industry, and is in the same range as ZTS (61) in the Pharmaceuticals Generic industry. This means that REGN's stock grew similarly to ABBV’s and similarly to ZTS’s over the last 12 months.
REGN's P/E Growth Rating (36) in the Biotechnology industry is in the same range as ABBV (40) in the Pharmaceuticals Major industry, and is somewhat better than the same rating for ZTS (86) in the Pharmaceuticals Generic industry. This means that REGN's stock grew similarly to ABBV’s and somewhat faster than ZTS’s over the last 12 months.
| ABBV | REGN | ZTS | |
|---|---|---|---|
| RSI ODDS (%) | 2 days ago 37% | N/A | 2 days ago 55% |
| Stochastic ODDS (%) | 2 days ago 58% | 2 days ago 58% | 2 days ago 68% |
| Momentum ODDS (%) | 2 days ago 47% | 2 days ago 46% | 2 days ago 54% |
| MACD ODDS (%) | 2 days ago 58% | 2 days ago 70% | 2 days ago 65% |
| TrendWeek ODDS (%) | 2 days ago 47% | 2 days ago 54% | 2 days ago 61% |
| TrendMonth ODDS (%) | 2 days ago 51% | 2 days ago 61% | 2 days ago 63% |
| Advances ODDS (%) | 3 days ago 57% | 11 days ago 64% | 3 days ago 52% |
| Declines ODDS (%) | 5 days ago 47% | 2 days ago 51% | 16 days ago 58% |
| BollingerBands ODDS (%) | 2 days ago 62% | 2 days ago 51% | 2 days ago 62% |
| Aroon ODDS (%) | 2 days ago 45% | 2 days ago 71% | 2 days ago 65% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| ION | 60.27 | 0.75 | +1.26% |
| ProShares S&P Global Cor Btty Mtls ETF | |||
| ERTH | 48.82 | 0.60 | +1.24% |
| Invesco MSCI Sustainable Future ETF | |||
| BUFX | 21.51 | N/A | N/A |
| FT Vest Laddered Enh & Mod Buffer ETF | |||
| SMDV | 72.21 | -0.49 | -0.67% |
| ProShares Russell 2000 Dividend Growers | |||
| VFH | 124.56 | -1.32 | -1.05% |
| Vanguard Financials ETF | |||
ABBV and
Correlation & Price change
A.I.dvisor indicates that over the last year, ABBV has been loosely correlated with BMY. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if ABBV jumps, then BMY could also see price increases.
| Ticker / NAME | Correlation To ABBV | 1D Price Change % | ||
|---|---|---|---|---|
| ABBV | 100% | -2.10% | ||
| BMY - ABBV | 58% Loosely correlated | -1.43% | ||
| PFE - ABBV | 57% Loosely correlated | -1.10% | ||
| BIIB - ABBV | 55% Loosely correlated | -2.34% | ||
| AMGN - ABBV | 54% Loosely correlated | -1.29% | ||
| NVS - ABBV | 53% Loosely correlated | -0.65% | ||
More | ||||
ZTS and
Correlation & Price change
A.I.dvisor indicates that over the last year, ZTS has been loosely correlated with ELAN. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if ZTS jumps, then ELAN could also see price increases.
| Ticker / NAME | Correlation To ZTS | 1D Price Change % | ||
|---|---|---|---|---|
| ZTS | 100% | -1.78% | ||
| ELAN - ZTS | 52% Loosely correlated | -1.41% | ||
| VTRS - ZTS | 44% Loosely correlated | -1.03% | ||
| PRGO - ZTS | 41% Loosely correlated | +2.45% | ||
| HLN - ZTS | 40% Loosely correlated | -0.40% | ||
| PAHC - ZTS | 39% Loosely correlated | -2.03% | ||
More | ||||